Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
27 November 2014. As a result of new data from the SIGNIFY study (1), presented at ESC Congress 2014 and published simultaneously in the New England Journal of Medicine, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has made recommendations aimed at reducing the risk of heart problems, including MI (heart attack) and bradycardia (slow heart rate) in patients prescribed ivabradine for angina (2).The PRAC recommendations have been endorsed by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in its final opinion. The CHMP opinion will be sent to the European Commission, which will issue a legally binding decision valid throughout the EU in due course.The ESC leadership and guidelines chairs have reviewed the PRAC recommendations in the context of all the current ESC guidelines that include mention of ivabradine. No revision of ESC guidelines is required since the EMA has not changed any of the indications for ivabradine, only specific prescribing information. A link to the EMA statement outlining the revised prescribing guidelines for ivabradine for the treatment of angina will be added to the ESC guidelines webpage and the EHJ website. The new EMA prescribing information for ivabradine for the treatment of angina is as follows:
1) Fox K, Ford I, Steg PG, et al, for the SIGNIFY Investigators. Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure N Engl J Med 2014; 371:1091-10992) Link to EMA statementESC Guidelines on the Management of Stable Coronary Artery Disease Main ESC Guidelines page
© 2017 European Society of Cardiology. All rights reserved